These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 25347122)

  • 1. Standard of care and promising new agents for triple negative metastatic breast cancer.
    Mancini P; Angeloni A; Risi E; Orsi E; Mezi S
    Cancers (Basel); 2014 Oct; 6(4):2187-223. PubMed ID: 25347122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer.
    Sayed-Ahmed MM; Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Aleisa AM; Al-Yahya AA; Alsheikh A; Al Diab AI; Al-Akeely MH
    Tumori; 2013; 99(4):545-54. PubMed ID: 24326846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapies in Triple-Negative Breast Cancer.
    Marmé F; Schneeweiss A
    Breast Care (Basel); 2015 Jul; 10(3):159-66. PubMed ID: 26557820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
    Papadimitriou M; Mountzios G; Papadimitriou CA
    Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
    Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
    Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer.
    Mezi S; Botticelli A; Pomati G; Cerbelli B; Scagnoli S; Amirhassankhani S; d'Amati G; Marchetti P
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
    Li Y; Zhan Z; Yin X; Fu S; Deng X
    Front Oncol; 2021; 11():731535. PubMed ID: 34778045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
    Tong L; Yu X; Wang S; Chen L; Wu Y
    Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.
    Barchiesi G; Roberto M; Verrico M; Vici P; Tomao S; Tomao F
    Front Oncol; 2021; 11():769280. PubMed ID: 34900718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-negative breast cancer: A run-through of features, classification and current therapies.
    Manjunath M; Choudhary B
    Oncol Lett; 2021 Jul; 22(1):512. PubMed ID: 33986872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].
    Nowacka-Zawisza M; Krajewska WM
    Postepy Hig Med Dosw (Online); 2013 Nov; 67():1090-7. PubMed ID: 24379250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research advances and new challenges in overcoming triple-negative breast cancer.
    Zong Y; Pegram M
    Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
    Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecularly targeted therapies for metastatic triple-negative breast cancer.
    Bayraktar S; Glück S
    Breast Cancer Res Treat; 2013 Feb; 138(1):21-35. PubMed ID: 23358903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
    Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.
    Jain V; Kumar H; Anod HV; Chand P; Gupta NV; Dey S; Kesharwani SS
    J Control Release; 2020 Oct; 326():628-647. PubMed ID: 32653502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
    Kelly CM; Buzdar AU
    Drugs; 2013 May; 73(6):505-15. PubMed ID: 23605692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.